Home / Contract Awards / FDA Selects Four Firms to Develop Automated Biological Product Reporting Methods

FDA Selects Four Firms to Develop Automated Biological Product Reporting Methods

The Food and Drug Administration has awarded four companies contracts worth up to $75M each to develop automated methods for reporting adverse drug events.

IBM (NYSE: IBM), Acumen, Dovel Technologies and IQVIA Government Solutions will use artificial intelligence, machine learning, natural language processing and other automation techniques to create data collection and analysis systems for the FDA’s Center for Biologics Evaluation and Research, the agency said Thursday in a FedBizOpps notice.

FDA requires each contractor to offer indirect access to medical information of U.S. patients, including administrative and claims data and electronic health records.

The indefinite delivery/indefinite quantity contracts have a five-year ordering period.

The agency also selected the four companies to develop surveillance tools as part of the Biologics Effectiveness and Safety Initiative.

Check Also

Arlington Capital Unveils New Aerospace Firm as Acquisition of Triumph Group’s Fabrication Business Closes

Arlington Capital Partners has formed a new company after the Washington, D.C.-based private equity firm …

Three Firms Get $1.06B in DLA Contract Modifications for Integrated Operating Room Components

Steris, Karl Storz Endoscopy-America and American Medical Depot have received contract modifications worth $1.06B combined …